Ophthalmology · Los Angeles, CA
NPI
1538265632
Since 2006
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
4278 W 3rd St
Los Angeles, CA, 90020
Phone (213) 366-0388
Groups this clinician bills Medicare through
Medicare paid, 2024
$802K
8,187 services
Medicare patients, 2024
986
Average age 78
Drug cost, 2024
$5.0M
14,958 prescriptions
Company payments, 2025
$1,803
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sok H Nam was code 92012 (ophthalmological e&m), 1,075 times for 724 patients. In total Sok H Nam billed 8,187 services in 35 codes, and Medicare paid $802K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-04-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 92012 Ophthalmological E&M | Office | 1,075 | 724 | $73.96 | $80K |
| 92083 Vision, Hearing, and Speech Services | Office | 945 | 850 | $54.54 | $52K |
| 92133 Computerized Ophthalmic Imaging | Office | 785 | 765 | $28.20 | $22K |
| 92020 Ophthalmological E&M | Office | 726 | 711 | $22.35 | $16K |
| 92250 Angiography | Office | 691 | 683 | $29.46 | $20K |
| 92014 Ophthalmological E&M | Office | 679 | 654 | $99.13 | $67K |
| 76514 Ultrasound - Nonspecific | Office | 491 | 485 | $8.91 | $4,374 |
| 92134 Computerized Ophthalmic Imaging | Office | 483 | 466 | $32.34 | $16K |
| 65855 Fluid Flow and Drainage of Eye (Any Method) | Office | 398 | 325 | $211.53 | $84K |
| 92286 Standard X-ray | Office | 356 | 353 | $31.71 | $11K |
| 68761 Eye | Office | 278 | 278 | $190.81 | $53K |
| 68801 Eye | Office | 220 | 214 | $127.15 | $28K |
| 92004 Ophthalmological E&M | Office | 172 | 172 | $121.93 | $21K |
| 92136 Ultrasound - Nonspecific | Office | 146 | 100 | $35.27 | $5,149 |
| 66991 Cataract Surgery | Facility | 106 | 73 | $320.42 | $34K |
By year: 2022 $990K for 10,185 services; 2023 $898K for 8,908 services; 2024 $802K for 8,187 services.
Medicare prescription drug claims, 2024
In 2024, the drug Sok H Nam prescribed most often to Medicare patients was Restasis (Cyclosporine), with 3,327 prescriptions and refills. In total Sok H Nam wrote 14,958 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Restasis Cyclosporine | 3,327 | 4,307 | 777 | $2.7M |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 1,531 | 3,149 | 440 | $25K |
| Lumigan Bimatoprost | 1,453 | 1,916 | 285 | $498K |
| Timolol Maleate Generic | 1,065 | 1,786 | 295 | $9,416 |
| Latanoprost Generic | 828 | 1,610 | 236 | $9,932 |
| Prednisolone Acetate Generic | 725 | 786 | 542 | $15K |
| Cyclosporine Generic | 708 | 1,065 | 306 | $296K |
| Ofloxacin Generic | 417 | 446 | 319 | $3,709 |
| Xiidra Lifitegrast | 407 | 531 | 115 | $356K |
| Ketorolac Tromethamine Generic | 391 | 1,071 | 320 | $5,249 |
| Miebo Perfluorohexyloctane/Pf | 371 | 448 | 132 | $308K |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 362 | 366 | 303 | $3,122 |
| Alphagan P Brimonidine Tartrate | 354 | 431 | 79 | $83K |
| Combigan Brimonidine Tartrate/Timolol | 319 | 456 | 65 | $88K |
| Rhopressa Netarsudil Mesylate | 257 | 334 | 57 | $103K |
Brand drugs: 9,240 claims; generic drugs: 5,718 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sok H Nam $1,803 ($1,803 in general payments such as food, travel and fees) from 6 companies. The largest payer was Bausch & Lomb Americas Inc. with $666.
| Company | Payments | Amount |
|---|---|---|
| Bausch & Lomb Americas Inc. BLCO | 34 | $666 |
| Abbvie Inc. ABBV | 26 | $548 |
| Glaukos Corporation GKOS | 7 | $321 |
| Thea Pharma Inc. | 7 | $154 |
| Alcon Vision LLC ALC | 2 | $58.67 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 2 | $55.84 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.